No retraction, correction or concern found when last checked on Nov 3, 2026.

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Guillaume Beaudoin-Bussières, Annemarie Laumaea, Sai Priya Anand and 16 more (opens in a new tab)

mBio · 2020 · CC BY

doi:10.1128/mbio.02590-20 (opens in a new tab)

Abstract

While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.

References 29

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006
No notice
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody · 2020
No notice
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
Effectiveness of convalescent plasma therapy in severe COVID-19 patients · 2020
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members — USS Theodore Roosevelt, April 2020 · 2020
No notice
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel · 2020
No notice
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques · 2020
No notice
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020
No notice
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity · 2020
No notice
29.
IgA dominates the early neutralizing antibody response to SARS-CoV-2 · 2021
No notice

Cited by papers we hold 10

Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination · 2023
Not checked
Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins · 2022
Not checked
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 · 2021
No notice
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset · 2021
Not checked
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial · 2021
Corrected
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond · 2021
No notice
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant · 2021
No notice
Humoral Responses and Serological Assays in SARS-CoV-2 Infections · 2020
No notice
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection · 2020
No notice
Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases · 2020
No notice

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.